Keiko I Greenberg1, Mara A McAdams-DeMarco2, Anna Köttgen3, Lawrence J Appel4, Josef Coresh5, Morgan E Grams4. 1. Departments of Medicine and kgreenb4@jhmi.edu. 2. Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland; 3. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland; Renal Division, University Medical Center Freiburg, Freiburg, Germany; and. 4. Departments of Medicine and Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland. 5. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland.
Abstract
BACKGROUND AND OBJECTIVES: Higher urate levels are associated with higher risk of CKD, but the association between urate and AKI is less established. This study evaluated the risk of hospitalized AKI associated with urate concentrations in a large population-based cohort. To explore whether urate itself causes kidney injury, the study also evaluated the relationship between a genetic urate score and AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 11,011 participants from the Atherosclerosis Risk in Communities study were followed from 1996-1998 (baseline) to 2010. The association between baseline plasma urate and risk of hospitalized AKI, adjusted for known AKI risk factors, was determined using Cox regression. Interactions of urate with gout and CKD were tested. Mendelian randomization was performed using a published genetic urate score among the participants with genetic data (n=7553). RESULTS: During 12 years of follow-up, 823 participants were hospitalized with AKI. Overall, mean participant age was 63.3 years, mean eGFR was 86.3 ml/min per 1.73 m(2), and mean plasma urate was 5.6 mg/dl. In patients with plasma urate >5.0 mg/dl, there was a 16% higher risk of hospitalized AKI for each 1-mg/dl higher urate (adjusted hazard ratio, 1.16; 95% confidence interval, 1.10 to 1.23; P<0.001). When stratified by history of gout, the association between higher urate and AKI was significant only in participants without a history of gout (P for interaction=0.02). There was no interaction of CKD and urate with AKI, nor was there an association between genetic urate score and AKI. CONCLUSIONS: Plasma urate >5.0 mg/dl was independently associated with risk of hospitalized AKI; however, Mendelian randomization did not provide evidence for a causal role of urate in AKI. Further research is needed to determine whether lowering plasma urate might reduce AKI risk.
BACKGROUND AND OBJECTIVES: Higher urate levels are associated with higher risk of CKD, but the association between urate and AKI is less established. This study evaluated the risk of hospitalized AKI associated with urate concentrations in a large population-based cohort. To explore whether urate itself causes kidney injury, the study also evaluated the relationship between a genetic urate score and AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 11,011 participants from the Atherosclerosis Risk in Communities study were followed from 1996-1998 (baseline) to 2010. The association between baseline plasma urate and risk of hospitalized AKI, adjusted for known AKI risk factors, was determined using Cox regression. Interactions of urate with gout and CKD were tested. Mendelian randomization was performed using a published genetic urate score among the participants with genetic data (n=7553). RESULTS: During 12 years of follow-up, 823 participants were hospitalized with AKI. Overall, mean participant age was 63.3 years, mean eGFR was 86.3 ml/min per 1.73 m(2), and mean plasma urate was 5.6 mg/dl. In patients with plasma urate >5.0 mg/dl, there was a 16% higher risk of hospitalized AKI for each 1-mg/dl higher urate (adjusted hazard ratio, 1.16; 95% confidence interval, 1.10 to 1.23; P<0.001). When stratified by history of gout, the association between higher urate and AKI was significant only in participants without a history of gout (P for interaction=0.02). There was no interaction of CKD and urate with AKI, nor was there an association between genetic urate score and AKI. CONCLUSIONS: Plasma urate >5.0 mg/dl was independently associated with risk of hospitalized AKI; however, Mendelian randomization did not provide evidence for a causal role of urate in AKI. Further research is needed to determine whether lowering plasma urate might reduce AKI risk.
Authors: G Würzner; J C Gerster; A Chiolero; M Maillard; C L Fallab-Stubi; H R Brunner; M Burnier Journal: J Hypertens Date: 2001-10 Impact factor: 4.844
Authors: Johan Sundström; Lisa Sullivan; Ralph B D'Agostino; Daniel Levy; William B Kannel; Ramachandran S Vasan Journal: Hypertension Date: 2004-11-29 Impact factor: 10.190
Authors: Laura G Sánchez-Lozada; Edilia Tapia; Pablo Bautista-García; Virgilia Soto; Carmen Avila-Casado; Iliana P Vega-Campos; Takahiko Nakagawa; Lin Zhao; Martha Franco; Richard J Johnson Journal: Am J Physiol Renal Physiol Date: 2008-01-23
Authors: Debbie A Lawlor; Roger M Harbord; Jonathan A C Sterne; Nic Timpson; George Davey Smith Journal: Stat Med Date: 2008-04-15 Impact factor: 2.373
Authors: Dorothea Nitsch; Mariam Molokhia; Liam Smeeth; Bianca L DeStavola; John C Whittaker; David A Leon Journal: Am J Epidemiol Date: 2006-01-12 Impact factor: 4.897
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Xue Li; Xiangrui Meng; Maria Timofeeva; Ioanna Tzoulaki; Konstantinos K Tsilidis; John PA Ioannidis; Harry Campbell; Evropi Theodoratou Journal: BMJ Date: 2017-06-07
Authors: Abutaleb Ahsan Ejaz; Takahiko Nakagawa; Mehmet Kanbay; Masanari Kuwabara; Ada Kumar; Fernando E Garcia Arroyo; Carlos Roncal-Jimenez; Fumihiko Sasai; Duk-Hee Kang; Thomas Jensen; Ana Andres Hernando; Bernardo Rodriguez-Iturbe; Gabriela Garcia; Dean R Tolan; Laura G Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson Journal: Semin Nephrol Date: 2020-11 Impact factor: 5.299
Authors: Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli Journal: Front Med (Lausanne) Date: 2018-05-31
Authors: Anand Srivastava; Ragnar Palsson; David E Leaf; Angelica Higuera; Margaret E Chen; Polly Palacios; Rebecca M Baron; Venkata Sabbisetti; Andrew N Hoofnagle; Sucheta M Vaingankar; Paul M Palevsky; Sushrut S Waikar Journal: Kidney Med Date: 2019-01-15